Cargando…

Anticancer effect of histone deacetylase inhibitor scriptaid as a single agent for hepatocellular carcinoma

Recurrence is one of the major causes of poor prognosis for patients with hepatocellular carcinoma (HCC), and drug resistance is closely associated with disease recurrence. Histone deacetylase (HDAC) inhibitor scriptaid functions as an anticancer agent in many different types of tumors, but its poss...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Linlin, Sun, Xiaoyang, Xie, Yu, Zhuang, Yinping, Yao, Ruosi, Xu, Kai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Portland Press Ltd. 2018
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6043718/ https://www.ncbi.nlm.nih.gov/pubmed/29945926 http://dx.doi.org/10.1042/BSR20180360

Ejemplares similares

Histone Deacetylase Inhibitor Scriptaid Alleviated Neurological Dysfunction after Experimental Intracerebral Hemorrhage in Mice
por: Yang, Heng, et al.
Publicado: (2018)

Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents
por: Ververis, Katherine, et al.
Publicado: (2013)

Histone Deacetylase Inhibitors as Anticancer Drugs
por: Eckschlager, Tomas, et al.
Publicado: (2017)

Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
por: Mottamal, Madhusoodanan, et al.
Publicado: (2015)

Histone deacetylase inhibitors as novel anticancer therapeutics
por: Walkinshaw, D.R., et al.
Publicado: (2008)

Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy
por: Verza, Flávia Alves, et al.
Publicado: (2020)

Antitheilerial Activity of the Anticancer Histone Deacetylase Inhibitors
por: Barman, Madhumanti, et al.
Publicado: (2021)

Anti-Proliferative Activity of HPOB against Multiple Myeloma Cells via p21 Transcriptional Activation
por: Liu, Linlin, et al.
Publicado: (2018)

Multitarget Anticancer Agents Based on Histone Deacetylase and Protein Kinase CK2 Inhibitors
por: Martínez, Regina, et al.
Publicado: (2020)

Therapeutic Strategies to Enhance the Anticancer Efficacy of Histone Deacetylase Inhibitors
por: Miller, Claudia P., et al.
Publicado: (2011)

Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy
por: Singh, Amit Kumar, et al.
Publicado: (2018)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro
por: Freese, Kim, et al.
Publicado: (2019)

Histone Deacetylase Inhibitors, Intrinsic and Extrinsic Apoptotic Pathways, and Epigenetic Alterations of Histone Deacetylases (HDACs) in Hepatocellular Carcinoma
por: Sanaei, Masumeh, et al.
Publicado: (2021)

Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors
por: Xu, Qing-Yu, et al.
Publicado: (2020)

Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer
por: Alzoubi, Samer, et al.
Publicado: (2016)

NBM-HD-1: A Novel Histone Deacetylase Inhibitor with Anticancer Activity
por: Huang, Wei-Jan, et al.
Publicado: (2012)

Synergistic Anticancer Effect of Glycolysis and Histone Deacetylases Inhibitors in a Glioblastoma Model
por: Pająk, Beata, et al.
Publicado: (2021)

Histone Deacetylase Inhibitors in the Treatment of Hepatocellular Carcinoma: Current Evidence and Future Opportunities
por: Garmpis, Nikolaos, et al.
Publicado: (2021)

The in vitro development of cloned sheep embryos treated with Scriptaid and Trichostatin (A)
por: Al-Ghadi, Muath Q, et al.
Publicado: (2020)

Treatment of chronic kidney diseases with histone deacetylase inhibitors
por: Liu, Na, et al.
Publicado: (2015)

HDAC inhibitor, scriptaid, induces glioma cell apoptosis through JNK activation and inhibits telomerase activity
por: Sharma, Vivek, et al.
Publicado: (2010)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
por: Tan, Jiahuai, et al.
Publicado: (2010)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Direct Amidation to Access 3-Amido-1,8-Naphthalimides Including Fluorescent Scriptaid Analogues as HDAC Inhibitors
por: Hearn, Kyle N., et al.
Publicado: (2021)

p53-dependent and p53-independent anticancer effects of different histone deacetylase inhibitors
por: Sonnemann, J, et al.
Publicado: (2014)

Improved Anticancer Activities of a New Pentafluorothio-Substituted Vorinostat-Type Histone Deacetylase Inhibitor
por: Goehringer, Nils, et al.
Publicado: (2021)

Liver-Targeting Class I Selective Histone Deacetylase Inhibitors Potently Suppress Hepatocellular Tumor Growth as Standalone Agents
por: Tapadar, Subhasish, et al.
Publicado: (2020)

Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?
por: Nolan, L, et al.
Publicado: (2008)

Histone deacetylase inhibitors in multiple myeloma
por: Deleu, Sarah, et al.
Publicado: (2009)

Histone deacetylase inhibitors in Hodgkin lymphoma
por: Buglio, Daniela, et al.
Publicado: (2010)

Clinical Toxicities of Histone Deacetylase Inhibitors
por: Subramanian, Srividya, et al.
Publicado: (2010)

Acetylation and Histone Deacetylase Inhibitors in Cancer
por: Kortenhorst, Madeleine S. Q., et al.
Publicado: (2006)

The application of histone deacetylases inhibitors in glioblastoma
por: Chen, Rui, et al.
Publicado: (2020)

Histone Deacetylases and Their Inhibitors in Cancer Epigenetics
por: Hassell, Kelly N.
Publicado: (2019)

The synergistic anticancer effect of the bromodomain inhibitor OTX015 and histone deacetylase 6 inhibitor WT-161 in osteosarcoma
por: Yu, Bo, et al.
Publicado: (2022)

Beyond Histone and Deacetylase: An Overview of Cytoplasmic Histone Deacetylases and Their Nonhistone Substrates
por: Yao, Ya-Li, et al.
Publicado: (2011)

Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8
por: Yan, Wensheng, et al.
Publicado: (2012)

Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors
por: Lapierre, Marion, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_fp66afed9ch8hajus471tr2usn